TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.

@article{Govers2014TCRsGL,
  title={TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.},
  author={C. J. L. R. Govers and Zsolt Sebesty{\'e}n and J{\'a}nos Roszik and Mandy van Brakel and Cor A. Berrevoets and {\'A}rp{\'a}d Sz{\"o}őr and Konstantina Panoutsopoulou and Marieke Broertjes and Tan Van and Gy{\"o}rgy Vereb and J{\'a}nos Sz{\"o}llősi and Reno Debets},
  journal={Journal of immunology},
  year={2014},
  volume={193 10},
  pages={5315-26}
}
Adoptive transfer of T cells that are gene engineered to express a defined TCR represents a feasible and promising therapy for patients with tumors. However, TCR gene therapy is hindered by the transient presence and effectiveness of transferred T cells, which are anticipated to be improved by adequate T cell costimulation. In this article, we report the identification and characterization of a novel two-chain TCR linked to CD28 and CD3ε (i.e., TCR:28ε). This modified TCR demonstrates enhanced… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS